Mitochondrial Inhibitor Models of Huntington's Disease and Parkinson's Disease Induce Zinc Accumulation and Are Attenuated by Inhibition of Zinc Neurotoxicity in vitro or in vivo

Christian T. Sheline^{a, d} Julia Zhu^d Wendy Zhang^d Chunxiao Shi^{b, d} Ai-Li Cai^{c, d}

^aDepartment of Ophthalmology and the Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, La., and Departments of ^bSurgery, ^cBiomedical Engineering and ^dNeurology, Washington University, Saint Louis, Mo., USA

Key Words

3-Nitropropionic acid • 6-Hydroxydopamine • N-methyl-4-phenylpyridium • Zinc neurotoxicity • Glycolytic inhibition

Abstract

Background: Inhibition of mitochondrial function occurs in many neurodegenerative diseases, and inhibitors of mitochondrial complexes I and II are used to model them. The complex II inhibitor, 3-nitropropionic acid (3-NPA), kills the striatal neurons susceptible in Huntington's disease. The complex I inhibitor N-methyl-4-phenylpyridium (MPP⁺) and 6-hydroxydopamine (6-OHDA) are used to model Parkinson's disease. Zinc (Zn²⁺) accumulates after 3-NPA, 6-OHDA and MPP⁺ in situ or in vivo. **Objective:** We will investigate the role of Zn²⁺ neurotoxicity in 3-NPA, 6-OHDA and MPP⁺. **Methods:** Murine striatal/midbrain tyrosine hydroxylase positive, or near-pure cortical neuronal cultures, or animals were exposed to 3-NPA or MPP⁺ and 6-OHDA with or without neuroprotective compounds. Intracellular zinc ([Zn²⁺]_i), nicotinamide adenine dinucleotide (NAD⁺), NADH, glycolytic intermediates and neurotoxicity were measured. **Results:** We showed that compounds or genetics which restore NAD⁺ and attenuate Zn²⁺ neurotoxicity (pyruvate, nicotinamide, NAD⁺, increased NAD⁺ synthesis, sirtuin inhibition or Zn²⁺

chelation) attenuated the neuronal death induced by these toxins. The increase in [Zn²⁺]_i preceded a reduction in the NAD⁺/NADH ratio that caused a reversible glycolytic inhibition. Pyruvate, nicotinamide and NAD⁺ reversed the reductions in the NAD⁺/NADH ratio, glycolysis and neuronal death after challenge with 3-NPA, 6-OHDA or MPP⁺, as was previously shown for exogenous Zn²⁺. To test efficacy in vivo, we injected 3-NPA into the striatum of rats and systemically into mice, with or without pyruvate. We observed early striatal Zn²⁺ fluorescence, and pyruvate significantly attenuated the 3-NPA-induced lesion and restored behavioral scores. **Conclusions:** Together, these studies suggest that Zn²⁺ accumulation caused by MPP⁺ and 3-NPA is a novel preventable mechanism of the resultant neurotoxicity.

Copyright © 2012 S. Karger AG, Basel

Introduction

An impairment of energy metabolism underlies neuronal death in neurodegenerative diseases (reviewed in [1]). Huntington's disease (HD) is a progressive neurodegenera-

J.Z. and W.Z. contributed equally to this work.
An abstract of this study has been presented at the Society for Neurosciences in 2003, New Orleans, La., USA

tive disorder characterized by chorea, psychiatric disturbances and dementia. The striatum is the primary site of neuronal loss in HD. The mechanism of neurodegeneration and the underlying cause of the selectivity for the striatum are thought to involve inhibition of mitochondrial electron transport at complex II and the selective vulnerability of the striatum to energy impairment [2, 3]. Chronic systemic injection of 3-nitropropionic acid (3-NPA, complex II inhibitor) into mice or rats induces bilateral striatal lesions with many neuropathological features of HD and, therefore, is widely used as a model of HD [4, 5]. Reactive oxygen species (ROS) have been suggested to play a substantial role in the neurotoxicity of 3-NPA-induced neuronal injury; effective antioxidants partially attenuate (up to 50%) 3-NPA lesions [6, 7]. These radicals cause intracellular and extracellular Zn^{2+} accumulation in slices exposed to 3-NPA as determined by Zn^{2+} fluorescence [8].

Oxidative stress is also thought to contribute to dopaminergic cell death in Parkinson's disease (PD) as evidenced by biochemical changes occurring in the substantia nigra (such as increased iron levels, inhibition of complex I activity and decreased glutathione levels) [9, 10]. The catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) has been shown to form endogenously in patients suffering from PD and its injection is used as an animal model of PD [11, 12].

The involvement of ROS in N-methyl-4-phenylpyridinium (MPP⁺) toxicity of dopamine-secreting neurons is unclear. Free-radical-sensitive fluorophores, as well as measurements of lipid peroxidation and vital dyes, were used to demonstrate increased production of ROS in dopaminergic neurons treated with 6-OHDA compared to MPP⁺ [13, 14]. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the precursor to MPP⁺, and both have been shown to induce Zn^{2+} release and an increase in intracellular zinc ($[Zn^{2+}]_i$) in degenerating striatal neurons in vivo and in situ [15, 16]. We recently showed that ROS induces an increase in $[Zn^{2+}]_i$ and a loss of nicotinamide adenine dinucleotide (NAD^+), causing inhibition of glycolysis and neuronal death; accordingly, preventing this increase or loss prevents this outcome [17].

In this study, we investigated the role of Zn^{2+} neurotoxicity in 3 neurotoxins (3-NPA, 6-OHDA and MPP⁺) commonly used as models for HD and PD. We examined $[Zn^{2+}]_i$, NAD^+ / $NADH$ levels, glycolytic inhibition and the efficacy of compounds and genotypes, which restore NAD^+ or reduce Zn^{2+} levels, to attenuate mitochondrial inhibition-mediated injury in vitro, and against 3-NPA injections in vivo. These compounds and genotypes were used due to their efficacy against Zn^{2+} neurotoxicity.

Experimental Procedures

Cell Culture and Toxicity Studies

Near-pure cortical neuronal cell cultures were prepared from E15 Swiss-Webster, C57/Bl6J, $ZnT3^{-/-}$, $MT3^{-/-}$, or Wallerian degeneration-slow (Wld^s) mice as previously described [18]. Cultures from striatum/midbrain of Swiss-Webster mice were prepared likewise (except at 12 hemispheres/plate), and the growth of glia was inhibited by feeding with Neurobasal medium A + B27 after 3 days [19].

Slow toxicity was initiated after 8 days in vitro, by exposure to 100–1,000 μM 3-NPA, 50–200 μM 6-OHDA or 5–400 μM MPP⁺ in MEM-defined media + 26 mM sodium bicarbonate and 21 mM glucose + 1 μM MK-801 and 50 ng/ml of brain-derived neurotrophic factor (BDNF, Cellsciences, Canton, Mass., USA). Due to the lack of glia, BDNF was included to prevent trophic deprivation, and MK-801 was included to prevent wash-induced glutamate release and excitotoxicity in near-pure neuronal cultures. The efficacy of pyruvate, lactate, thiamine or nicotinamide (10 mM), 6 mM NAD^+ , 10 μM sirtinol or 10 μM N,N,N',N'-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN, specific $[Zn^{2+}]_i$ chelator) were tested after dose-finding experiments determined these concentrations to maximally reduce toxicities. Cell death was assayed 24–48 h later by lactate dehydrogenase efflux to the bathing medium, or by staining with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or by staining with propidium iodide (PI), with an $n = 9$ –12 for each condition [20]. Toxicity mediated by 3-NPA takes more time to occur than MPP⁺ or 6-OHDA toxicities (death starts at 18 ± 2 h vs. 4 ± 1 h; $n = 9$ –12).

Zinc Staining

Near-pure cortical neuronal cultures were loaded with 5 μM Fluo-Zin3-AM for 30 min at 37°C. Cultures were exposed to 800 μM 3-NPA and 200 μM 6-OHDA, 400 μM MPP⁺, 25 μM ethacrynic acid and 80 μM H_2O_2 (ROS generators, positive control). Increases in Fluo-Zin3 fluorescence began at 6 h for 3-NPA and peaked at 8–12 h, began at 2 h for the other toxins and peaked at 3 h. Increases in Fluo-Zin3 fluorescence were seen in striatal/midbrain cultures at lower levels of toxins (5 μM MPP⁺), but with similar kinetics. Striatal/midbrain cultures were coloaded with 5 μM Fluo-Zin3 (Invitrogen/Life Technologies, Carlsbad, Calif., USA) and 10 μM 5–7-dihydroxytryptamine (weakly identifies dopaminergic neurons) [19], and then exposed to 5 μM MPP⁺ for 3 h. Epifluorescence photomicrographs were taken at equivalent exposures at 485/530 for Fluo-Zin3 and 360/450 for 5–7-dihydroxytryptamine. For Zn^{2+} fluorescence in striatal sections, mice were sacrificed after $7 \times$ 3-NPA injections (50 mg/kg i.p. $2 \times$ /day) and fresh frozen sections of striatum were made, dried and immediately stained in 5 μM Zinpyr-1 (ZP1, TefLabs, Galveston, Tex., USA) for 2 min, and washed $3 \times$ in phosphate-buffered saline (PBS). Epifluorescence photomicrographs were then taken at equivalent exposures at 485/530.

Immunofluorescent Technique

Near-pure striatal/midbrain neuronal cultures were fixed, permeabilized in 0.4% Triton X-100, blocked in 10% normal goat serum, incubated with the primary antibody (anti-tyrosine hydroxylase (1:1,000), Chemicon/Millipore, Billerica, Mass., USA)

and developed using goat anti-mouse-CY3 secondary antibodies (1:200). Tyrosine hydroxylase positive neurons (TH⁺, >300/pit for control) that remained in each pit were counted.

Determination of NAD⁺ and NADH Levels

Near-pure cortical neuronal cultures (7–9 DIV), were used for the NAD⁺ and NADH measurements; cultures were exposed to 800 μ M 3-NPA, or to 400 μ M MPP⁺ or 200 μ M 6-OHDA. Cultures were then washed and lysed by addition of 75% ethanol-0.05 M K₂HPO₄ after toxin exposure. NAD⁺ and NADH were measured as described [21]. The NAD⁺/NADH ratio decreased starting at 12–14 h after 3-NPA exposure and was maximally reduced at 18 h, whereas it decreased starting at 3 h and was maximally reduced at 4 h for MPP⁺ and 6-OHDA which is just prior to the onset of cell death (data not shown).

Determination of Dihydroxyacetone Phosphate and Fructose Bisphosphate

Dihydroxyacetone phosphate (DHAP) and fructose bisphosphate (FBP) measurements were made on neuronal cell lysates prepared at the same timepoints and conditions, but were lysed by addition of 6% perchloric acid and protein precipitated by addition of potassium carbonate to pH 3.5. DHAP and FBP were measured as described [21].

In vivo Studies of Injections of 3-NPA into Rats or Mice

Long-Evans male rats (body weight: 250–300 g, Charles Rivers, Wilmington, Del., USA), C57/BL6J mice (Jackson Laboratories, Bar Harbor, Me., USA), or Wld^s mice (Harlan, Loughborough, UK) were used in this study. Six rats or mice were used for each condition studied. Housing and anesthesia concurred with guidelines established by the Washington University and LSUHSC institutional Animal Studies Committee, and were in accordance with the PHS Guide for the Care and Use of Laboratory Animals, USDA regulations and the AVMA Panel on Euthanasia guidelines. Two groups of 6 rats were anesthetized with 40 mg/kg pentobarbital intraperitoneally (i.p.), placed into a stereotax and injected with 750 nmol of 3-NPA in the presence or absence of 400 nmol of pyruvate by direct stereotaxic microinjection into the striatum at 2 μ l/min (0.5 mm anterior bregma, 2.6 mm lateral bregma, 5 mm ventral bregma; the syringe was left in for 5 min after injection). Animals were monitored for 24 h and perfused with cold PBS on day 3 for 2,3,5-triphenyl tetrazolium chloride (TTC) staining. Subacute systemic intraperitoneal injections of 3-NPA in 16-week-old C57/BL6 mice were performed as described [4]. Six Wld^s male mice aged 16 weeks were similarly exposed to 3-NPA. The surviving, nonakinetic animals from each of the 4 groups of 6 mice were behavior-tested and perfused for TTC staining on the evening of their last 3-NPA injection.

Morphometric Analysis of Infarct Volume

Infarct volumes were measured by morphometric analysis of infarct areas that were defined by a lack of staining in 2% TTC of 1- or 2-mm coronal sections using mouse or rat brain matrices, respectively (Harvard Bioscience, South Natick, Mass., USA). A cross-sectional area of the nonstained region for each brain slice was determined using an image analyzer (DUMAS, Drexel University, Philadelphia, Pa., USA) as described [22].

Semi-Quantitative Behavior Scoring of Mice

Mice were tested just prior to euthanasia for clasping, grasping strength and gait, using the tail inversion, inverted-screen and footprint-mapping tests. Animals were scored 0–5 by a rater blinded to the experimental conditions; scores from all 3 tests were added for each mouse, and results are presented as mean $\pm$ SEM (n = 6). For tail inversion: 0 = dead, 1 = akinetic, 2 = curled into a ball, 3 = major clasping, 4 = minor clasping and 5 = no clasping. For inverted screen: 0 = dead, 1 = nongrasping/akinetic, 2 = holding on for less than 2 s, 3 = holding on for 2–6 s, 4 = holding on for 6–12 s, and 5 = holding on for longer than 12 s or ‘climb over’. For footprint mapping: 0 = dead, 1 = akinetic, 2 = hindlimb dragging, 3 = footprint nonoverlap >1.5 cm, 4 = footprint nonoverlap 0–1.5 cm, and 5 = complete footprint overlap. Out of six 3-NPA- or 3-NPA + lactate-exposed mice, 3 or 2 died respectively, whereas only 1 Wld^s mouse and no 3-NPA + pyruvate-exposed mice died.

Data Analysis and Statistics

The changes in neuronal death and intracellular NAD⁺ ([NAD⁺]_i) were determined in cultures under the conditions and genotypes stated. The mean $\pm$ SEM were plotted and the n given for each experiment in the figure legends. Results were compared to sham-wash or saline-injection controls, as well as to toxin or injury exposure alone. One-way ANOVA was used to assess variance in each set of experiments, followed by a Bonferroni test. Significance was achieved by a p value of less than 0.05.

Reagents

Unless otherwise stated, all reagents were from Sigma Chemical Co. (St. Louis, Mo., USA).

Results

MPP⁺, 6-OHDA and 3-NPA Caused Intracellular Zinc Release

The toxins studied here (MPP⁺, 6-OHDA and 3-NPA) have been reported to induce ROS, and ROS have been shown to induce [Zn²⁺]_i release [17]. We show that 3 or 8 h after exposure of striatal/midbrain or cortical neuronal cultures to toxic levels of these compounds (fig. 1a, b), [Zn²⁺]_i levels are optimally increased as measured using Fluo-Zin3 fluorescence dye microscopy. The increase observed in cortical neurons is equal to, or for 3-NPA greater than, the strong ROS generators, H₂O₂, or ethacrynic acid (quantified in fig. 1c). 5–7, Dihydroxy-tryptamine is at best a weak fluorescent marker for TH⁺ neurons [19], and Fluo-Zin3 fluorescence was also shown to increase after MPP⁺ exposure in these neurons. The increase in [Zn²⁺]_i was oxidant mediated and specific for zinc because trolox (antioxidant) and TPEN partially and fully attenuated the increase in [Zn²⁺]_i after 3-NPA, respectively (fig. 1c). The partial efficacy of antioxidants against each of these neurotoxins has been reported previously [19, 23, 24].

Fig. 1. Exposure to mitochondrial toxins induces an increase in $[Zn^{2+}]_i$ in dopamine-containing striatal/midbrain neurons and in cortical neurons. **a** Striatal/midbrain cultures were coloaded with 5 μ M Fluo-Zin3-AM ($[Zn^{2+}]_i$) and 10 μ M 5–7-dihydroxytryptamine (TH^+), and then exposed to 5 μ M MPP⁺ for 3 h. Epifluorescence photomicrographs were taken at equivalent exposures for the control and MPP⁺ exposed cultures at 485/530 for Fluo-Zin3, and at 360/450 for 5–7-dihydroxytryptamine. **b** Near-pure neuronal cultures were loaded with 5 μ M Fluo-Zin3-AM and exposed to 800 μ M 3-NPA for 3 or 8 h, or to 400 μ M MPP⁺, 200 μ M 6-OHDA, 25 μ M ethacrynic acid (Eth) or 80 μ M H₂O₂ for 3 h, and photomicrographs were taken as above. **c** The photomicrographs were quantitated using SISAnalysis software, and normalized to control levels. * Significant difference from control. # Significant difference from 3-NPA exposure at $p < 0.05$ by a Bonferonni test. Bars indicate 50 μ m.

Compounds That Increase NAD⁺ Levels Prevented 3-NPA, 6-OHDA and MPP⁺ Toxicity

The concentrations and time courses of the neurotoxins were chosen to result in approximately 50% neuronal death. The concentrations of compounds used to attenuate toxicity were optimized (data not shown). The therapeutic compounds pyruvate, nicotinamide, NAD⁺, sirti-

nol and TPEN were demonstrated to attenuate death induced by 3-NPA and MPP⁺ in near-pure cortical neuronal cultures to varying extents (fig. 2). Sirtinol is an inhibitor of the sirtuin pathway, which is an NAD⁺ catabolic deacetylase enzyme involved in transcriptional regulation. Neurotoxicity induced by 6-OHDA was not responsive to Zn²⁺ chelation (TPEN) or Zn²⁺ excess, but was

Fig. 2. Pyruvate, nicotinamide, sirtinol, TPEN and NAD⁺ attenuate neurotoxicity in PNC cultures induced by 3-NPA, 6-OHDA and MPP⁺. Near-pure cortical neuronal cultures were exposed as indicated. LDH released to the bathing medium after 24–48 h is plotted (mean $\pm$ SEM, n = 9–12 cultures per condition); plot is scaled to the level associated with near complete neuronal death (produced by exposure to 20 μ M A23187 for 24 h = 100). *, #, + Difference from neurotoxin exposure alone at p < 0.05 by 1-way ANOVA followed by a Bonferroni test.

responsive to the restoration of NAD⁺ levels (pyruvate, nicotinamide, NAD⁺ and sirtinol). In contrast, equivalent concentrations of lactate were less effective than pyruvate for all toxins; lactate maintained partial efficacy for 3-NPA and 6-OHDA, but not for MPP⁺. Thiamine, a pyruvate dehydrogenase and α -ketoglutarate dehydrogenase cofactor, was ineffective for all toxins. Pyruvate, nicotinamide, lactate, thiamine and NAD⁺ do not chelate Zn²⁺ [17, 25]. Other than lactate, the beneficial compounds increase the intracellular concentration of NAD⁺ (table 1 and [17]). The number of TH⁺ neurons was reduced by lower toxin exposures and restored by pyruvate, NAD⁺ and TPEN in striatal/midbrain cultures, confirming that similar mechanisms are involved in TH⁺ neurons (fig. 3).

3-NPA, 6-OHDA and MPP⁺ Decreased the NAD⁺/NADH Ratio, Which Was Prevented by Pyruvate, Nicotinamide and NAD⁺

Near-pure cortical neuronal cultures were exposed to 3-NPA for 18 h and to MPP⁺ and 6-OHDA for 4 h (prior to cell death), which were optimal timepoints for the loss of metabolic intermediates (data not shown). Cultures were assayed for total NAD⁺ and NADH content as stated in the Experimental Procedures section. These neurotox-

ins all induced a substantial decrease in NAD⁺ levels, and the effect was greatest for 6-OHDA. However, only MPP⁺ (and not 6-OHDA) induced a substantial increase in NADH levels, as expected for a mitochondrial complex I inhibitor. Extracellular pyruvate, nicotinamide and NAD⁺ prevented the decrease in [NAD⁺]_i levels for each neurotoxin; pyruvate did so at the expense of NADH levels, thereby restoring the NAD⁺/NADH ratio. Lactate did not significantly prevent the decrease in the NAD⁺/NADH ratio (table 1).

3-NPA, 6-OHDA and MPP⁺ Caused DHAP and FBP Accumulation Indicative of GAPDH Inhibition

Cultures were similarly exposed and assayed for DHAP and FBP content as already stated. These neurotoxins (3-NPA, 6-OHDA and MPP⁺) all induced a substantial increase in these glycolytic intermediates indicative of glycolytic inhibition at GAPDH. The increase in DHAP and FBP was greatest for 3-NPA. Extracellular pyruvate, nicotinamide and NAD⁺ restored the intracellular levels of DHAP and FBP, demonstrating that the glycolytic inhibition was indirect and mediated through the NAD⁺/NADH ratio. Lactate partially reduced the increase in DHAP and FBP levels after 3-NPA, but not to the extent of pyruvate or NAD⁺ (table 2).

Table 1. 3-NPA, 6-OHDA and MPP⁺ each reduce the NAD⁺/NADH ratio

Condition	NAD ⁺ (nmol/plate ± SEM)	NADH (nmol/plate ± SEM)	NAD ⁺ / NADH ratio (± SEM)
Sham wash	4.06 ± 0.22	0.85 ± 0.12	4.8 ± 0.46
1 mM 3-NPA	2.01 ± 0.41*	0.99 ± 0.16	2.0 ± 0.71*
3-NPA + pyruvate	3.28 ± 1.34 [#]	0.41 ± 0.21 [#]	8.0 ± 1.66*, [#]
3-NPA + lactate	2.68 ± 0.69*	1.1 ± 0.25	2.44 ± 1.0*
3-NPA + nicotinamide	5.61 ± 0.86 [#]	0.99 ± 0.07	5.7 ± 1.01 [#]
3-NPA + NAD ⁺	6.2 ± 0.98 [#]	1.1 ± 0.27	5.6 ± 1.16 [#]
400 μM MPP ⁺	1.95 ± 0.40*	2.36 ± 0.58*	0.83 ± 0.96*
MPP ⁺ + pyruvate	2.86 ± 0.48*, [#]	1.14 ± 0.20 [#]	2.5 ± 0.76*, [#]
MPP ⁺ + lactate	1.80 ± 0.43*	2.55 ± 0.70*	0.71 ± 0.99*
MPP ⁺ + nicotinamide	4.31 ± 0.38 [#]	2.25 ± 0.41*	1.9 ± 0.85*, [#]
MPP ⁺ + NAD ⁺	5.93 ± 0.46 [#]	2.17 ± 0.48*	2.7 ± 0.96*, [#]
200 μM 6-OHDA	0.22 ± 0.03*	0.64 ± 0.03	0.34 ± 0.10*
6-OHDA + pyruvate	2.04 ± 0.29 [#]	0.61 ± 0.18	3.3 ± 0.61*, [#]
6-OHDA + nicotinamide	1.88 ± 0.12 [#]	0.63 ± 0.14	3.0 ± 0.46*, [#]
6-OHDA + NAD ⁺	4.2 ± 0.32 [#]	0.90 ± 0.19	4.7 ± 0.62 [#]

Near-pure cortical neuronal cultures were exposed to 3-NPA for 18 h, and to MPP⁺ or 6-OHDA for 4 h as indicated. NAD⁺ and NADH levels were measured prior to cell death (nmol/plate ± SEM, n = 6–9 measurements per condition).

* Significant difference from sham-wash control.

[#] Significant difference from neurotoxin alone at p < 0.05 by 1-way ANOVA followed by a Bonferroni test.

Table 2. 3-NPA, MPP⁺ and 6-OHDA increase levels of DHAP and FBP which are restored by pyruvate, nicotinamide or NAD⁺

Condition	DHAP (nmol/ plate ± SEM)	FBP (nmol/ plate ± SEM)
Sham wash	2.0 ± 0.7	2.1 ± 0.9
1 mM 3-NPA	10.1 ± 0.2*	20.5 ± 5.9*
3-NPA + pyruvate	2.9 ± 0.2 [#]	4.4 ± 0.2*, [#]
3-NPA + lactate	6.2 ± 0.4*, [#]	8.9 ± 1.2*, [#]
3-NPA + NAD ⁺	3.4 ± 0.4 [#]	4.9 ± 0.2*, [#]
400 μM MPP ⁺	3.7 ± 0.2*	4.0 ± 0.3*
MPP ⁺ + nicotinamide	1.9 ± 0.3 [#]	2.5 ± 0.2 [#]
MPP ⁺ + NAD ⁺	2.2 ± 0.3 [#]	2.6 ± 0.2 [#]
200 μM 6-OHDA	7.2 ± 0.7*	8.4 ± 0.8*
6-OHDA + pyruvate	2.2 ± 0.6 [#]	2.4 ± 0.7 [#]
6-OHDA + nicotinamide	2.4 ± 0.4 [#]	2.9 ± 0.5 [#]
6-OHDA + NAD ⁺	2.5 ± 0.6 [#]	3.1 ± 0.4 [#]

Near-pure cortical neuronal cultures were exposed to 3-NPA for 18 h, and to MPP⁺ or 6-OHDA for 4 h as indicated. DHAP and FBP levels were measured prior to cell death (nmol/plate ± SEM, n = 6–9 measurements per condition).

* Significant difference from sham-wash control.

[#] Significant difference from neurotoxin alone at p < 0.05 by 1-way ANOVA followed by a Bonferroni test.

Fig. 3. Pyruvate, TPEN and NAD⁺ attenuate TH⁺ neuronal loss in striatal/midbrain cultures induced by 3-NPA, 6-OHDA and MPP⁺. Striatal/midbrain neuronal cultures from Swiss-Webster mice were exposed as indicated. The percentage of TH⁺ neuronal death after 24–48 h is plotted (mean ± SEM, n = 6–9 cultures per condition). *, #, + Difference from neurotoxin exposure alone at p < 0.05 by 1-way ANOVA followed by a Bonferroni test.

Fig. 4. Pyruvate (P) reduced the infarct volume induced by intra-stratial injection of 3-NPA. **a** 3-NPA (750 nmol) was injected into the striatum of rats in the presence or absence of 400 nmol of pyruvate, and TTC staining was performed after 3 days as indicated. Each row shows the injured tissue from a different animal that was exposed as indicated. **b** The lesion volume was measured. Average ± SEM, (n = 6) is presented. * Difference from neurotoxin exposure alone at p < 0.05 by 1-way ANOVA followed by a Bonferroni test.

Fig. 5. Pyruvate (P) or a Wld^s genotype reduced the infarct volume caused by i.p. 3-NPA in mice. **a–d** 3-NPA (9 injections of 50 mg/kg 2×/day) was injected i.p. into C57/Bl6 or Wld^s mice with or without 500 mg/kg i.p. of pyruvate or lactate (once per day starting 1 day before), and TTC staining was performed after 7 days as indicated. Each row shows the injured tissue from a different animal that was exposed as indicated. **a** Coronal sections of 2 different

3-NPA-injected C57/Bl6 mice are shown to demonstrate the bilateral lesion. **b** One hemisphere of 2 different 3-NPA-injected C57/Bl6 mice is shown (other half saved for biochemical assays). **c** One hemisphere of 2 different 3-NPA + pyruvate-injected C57/Bl6 mice is shown. **d** The lesion volume was measured and the average $\pm$ SEM (n = 6) is presented. * Difference from neurotoxin exposure alone at p < 0.05 by 1-way ANOVA followed by a Bonferroni test.

Injections of 3-NPA Induced Striatal Lesions Which Could Be Prevented by Pyruvate, Nicotinamide, but Not by Lactate

Long-Evans male rats were injected with high doses of 3-NPA into the striatum (750 nmol) in the presence or absence of pyruvate; lesion volume was determined after 3 days. We also determined lesion volumes induced by 9 low-dose intraperitoneal injections of 3-NPA into mice. Pyruvate attenuated the lesions in both the rat intrastriatal injections (fig. 4) and in the mouse intraperitoneal injections (fig. 5). Nicotinamide, but not lactate, was also effective at attenuating lesions induced both by intrastriatal or intraperitoneal injections of 3-NPA (data not shown, fig. 4) [26]. Furthermore, Wld^s mice also had smaller lesions after 3-NPA administration. Cortical neuronal cultures derived from Wld^s mice were also resistant to each of the 3 toxins, and the therapeutic compounds further attenuated neurotoxicity (online suppl. fig. 1b; for all online supplementary material, see www.karger.com/doi/10.1159/000336558). Cortical neuronal cultures derived from mice with a genetic deletion of the Zn²⁺ homeostatic proteins, zinc transporter 3 (ZnT3 KO, no synaptic zinc), or metallothionein 3 (MT3 KO, reduced [Zn²⁺]_i) were not significantly different in their sensitivities to the toxins (online suppl. fig. 1a).

Injections of 3-NPA Induced Behavioral Deficits That Could Be Prevented by Pyruvate, but Not by Lactate

Figure 6 shows the mean $\pm$ SEM of the summed scores from 3 behavioral tests of each mouse: inverted screen, tail inversion and footprint mapping. The results from each individual test were similar to the combined results. In the animals receiving 3-NPA alone (that scored 0, 0, 0, 10, 9 and 5) or 3-NPA + lactate (that scored 0, 0, 3, 10, 10 and 7), 50% were dead or completely moribund, and the gait and strength of the remainder were very abnormal at the time of sacrifice. In those mice receiving pyruvate (that scored 15, 15, 15, 11, 10 and 10), all were active and had a nearly normal gait, normal strength and little clasping behavior. In Wld^s mice (that scored 0, 10, 12, 10, 9 and 7), one mouse died and the behavioral deficits in the remainder were intermediate (fig. 6).

Discussion

We have previously demonstrated that exogenous Zn²⁺ [21, 27] or oxidant-induced [Zn²⁺]_i release [17] causes selective loss of NAD⁺ levels, glycolytic inhibition (causing a buildup of the intermediates DHAP and FBP), ATP depletion and neuronal death. Manipulations that prevent Zn²⁺ accumulation (chelation) or restore NAD⁺ levels (exposure to pyruvate, nicotinamide, NAD⁺ and sir-

Fig. 6. Pyruvate reduced the gait deficits induced by i.p. 3-NPA. Before euthanizing the animals from figure 5, behavioral testing was performed as stated. The scores on the 3 semi-quantitative behavioral tests (0–5) were measured and summed for each animal, and the average $\pm$ SEM, ($n = 6$) is presented. * Difference from neurotoxin exposure alone at $p < 0.05$ by 1-way ANOVA followed by a Bonferroni test.

tuin pathway inhibitors or the use of Wld^s neurons) allow for glycolytic flux and reduce Zn²⁺-mediated neurotoxicities in vitro and in vivo. Zn²⁺ chelation attenuates 3-NPA and MPP⁺ toxicity and pyruvate, nicotinamide and the direct application of NAD⁺ attenuate 3-NPA, MPP⁺ and 6-OHDA toxicities. These data strongly implicate a reduction in the NAD⁺/NADH ratio as an important mechanism, with Zn²⁺-mediation for 3-NPA and MPP⁺ (see: this paper and [26]). Zn²⁺ accumulation has now been demonstrated for each of these neurotoxins in vitro and for 3-NPA and MPTP in vivo (online suppl. fig. 2 and [8, 15, 16]). Because subacute 3-NPA lesions form over 5–7 days, Zn²⁺ chelator studies are difficult to perform, requiring multiple intracerebral ventricular injections. ROS have been implicated in both the toxicities of these compounds and in the diseases they model, and antioxidants were shown to be partially effective (reviewed in [28, 29]). Studies of these toxins suggest that their mechanisms of injury rely on ROS generation induced by mitochondrial inhibition (reviewed in [30, 31]). ROS scavengers protect against each of these neurotoxins [19, 23, 24]. In addition, a combination of an antioxidant and a mitochondrial activator improves motor performance and extends survival in the R6/2-expanded polyglutamine repeat mouse model of HD [32]. Mitochondrial dysfunction has also been demonstrated in patients

and in genetic models of PD (e.g. parkin and synuclein), and in patients and genetic models of HD (CAG repeat models) (reviewed in [33–35]).

However, 6-OHDA toxicity, when compared to MPP⁺ or 3-NPA toxicity was relatively unresponsive to sirtuin inhibition, Zn²⁺ chelation or Zn²⁺ loading (fig. 2, 3). This may be because 6-OHDA had already induced maximal NAD⁺ loss through an alternate mechanism (table 1), such that Zn²⁺-mediated loss of NAD⁺ is less important. We suggest that the ROS generated by these toxins cause the Zn²⁺ release and accumulation. The differential cell selectivity of these inhibitors likely results from a combination of their differential uptake or activation and the differential susceptibility of the vulnerable regions to oxidative stress and mitochondrial dysfunction [3, 30]. For 3-NPA and MPP⁺, the increase in [Zn²⁺]_i could cause the loss of NAD⁺, or it could exacerbate the NAD⁺ loss induced by the toxins.

MPP⁺ (but not 6-OHDA) induced a reduction in NAD⁺ levels with a proportionate increase in NADH levels, which resulted in glycolytic inhibition. This is consistent with the known inhibition of mitochondrial NADH dehydrogenase by MPP⁺. 3-NPA, and particularly 6-OHDA, induced a reduction in NAD⁺ levels without an increase in NADH levels. This suggests a mechanism involving catabolism of NAD⁺ that results in a block of glycolysis (tables 1, 2). Restoration of NAD⁺ levels by pyruvate, nicotinamide or NAD⁺ prevents glycolytic inhibition and death, irrespective of the source of the dyshomeostasis in the NAD⁺/NADH ratio. Because 6-OHDA is unresponsive to Zn²⁺ chelation, it is also possible that it acts through a non-Zn²⁺-mediated mechanism to induce NAD⁺ loss, perhaps by activating poly-ADP ribosyl polymerase (PARP) (online suppl. fig. 3). PARP is activated by 3-NPA and MPTP, causing a loss of NAD⁺ levels; PARP inhibition is effective against these neurotoxicities in vivo [26, 36–38]. A similar PARP-mediated mechanism has not been reported for 6-OHDA neurotoxicity, though the dramatic loss of NAD⁺ levels and the efficacy of nicotinamide suggest that PARP-1 knockout animals should be partially resistant to 3-NPA and 6-OHDA, as has been shown for MPTP [39]. Wld^s mice overexpressed the NAD⁺ synthetic enzyme NMNAT1, allowing better NAD⁺ restoration [40], and they had reduced susceptibility to MPTP-induced nigrostriatal degeneration [41]. They also displayed a dramatically reduced cell loss and Zn²⁺ fluorescence after target deprivation [17], as well as a modestly reduced 3-NPA lesion volume (fig. 5). Measurements of wild-type and Wld^s striatal NAD⁺ levels after 3-NPA exposure are

ongoing. Neurons derived from Wld^s mice were resistant to each of these mitochondrial toxins, and were synergistic with nicotinamide (online suppl. fig. 1), which mimics its effect on neuronal death mediated by another Complex I inhibitor, rotenone [42]. Neurons from ZnT3 KO or MT3 KO were not resistant to toxicity from 3-NPA, 6-OHDA or MPP⁺. ZnT3 is the Zn²⁺ transporter which loads synaptic zinc [43]. MT3 is the metallothionein present in neurons, and is a zinc homeostatic protein and an antioxidant [44]. The ZnT3 KO data is not surprising because synaptic release of zinc is unlikely to be involved in vitro due to the large culture volumes. However, the lack of effect of MT3 KO on neuronal toxicity is somewhat surprising, and suggests that the role of MT3 as an antioxidant protein is equally important as its role as an [Zn²⁺]_i homeostasis protein in these in vitro toxicities.

We demonstrate here that when the [NAD⁺]_i levels were maintained by pyruvate conversion to lactate, by nicotinamide precursor supplementation (and NAD⁺ catabolic blocker), or by direct extracellular NAD⁺ supplementation, then glycolytic inhibition and death induced by mitochondrial toxins were prevented. Pyruvate was previously shown to attenuate MPP⁺-induced and 6-OHDA-induced neurotoxicities. However, the mechanism for this efficacy was suggested to be due to its antioxidant capabilities, whereas here we demonstrate that pyruvate acts by restoring the NAD⁺/NADH ratio [45–47]. Powerful ROS scavengers have only been shown to moderately attenuate (<50%) these mitochondrial inhibitors, whereas pyruvate was more efficacious both in vitro and in vivo. Also, pyruvate is not an antioxidant in the usual sense of absorbing excess electrons. Rather, its antioxidant effect results from the ability of alpha-ketoacids to undergo nonenzymatic decarboxylation in the pres-

ence of H₂O₂ causing their mutual destruction [48]. By withdrawing H₂O₂, this mildly reduces levels of other oxidative species via Fenton chemistry reactions. Pyruvate was ineffective against redox active metal toxicity (Cu²⁺, Cd²⁺) and much less effective against ethacrynic acid or menadione toxicities (ROS-mediated), suggesting its relative weakness as a normal antioxidant [22, 49, 50]. We suggest that pyruvate (and nicotinamide or NAD⁺) restores the NAD⁺/NADH ratio, whether the cause of the decrease is complex 1 inhibition (MPP⁺), PARP-1 activation (MPP⁺ or 6-OHDA), or Zn²⁺-mediated NAD⁺ loss (3-NPA or MPP⁺). This restoration of the NAD⁺/NADH ratio allows glycolytic flux. Exogenous lactate is unable to restore the NAD⁺/NADH ratio, but may be beneficial to remaining astrocytes or as an additional energy substrate.

Thiamine had no beneficial effect on 3-NPA, 6-OHDA or MPP⁺ neurotoxicity. This suggests that in contrast to redox active metals or exogenous oxidative agents, direct ROS-mediated pyruvate dehydrogenase or α -ketoglutarate dehydrogenase inhibition might not be involved in the neurotoxicity of these neurotoxins. These data suggest that 3-NPA and MPP⁺ cause a ROS-mediated insult leading to Zn²⁺ accumulation and NAD⁺ loss resulting in glycolytic blockade, which are all necessary for neuronal death. Non-Zn²⁺-mediated NAD⁺ loss, especially for 6-OHDA, also contributes to neuronal death. It also suggests that these compounds should be investigated for their efficacy against HD and PD.

Acknowledgements

We would like to thank Darlene Guillot for assistance with graphics and Ryan Labadens for scientific editing. This work was funded by NIH grants NS030337 and DK073446 (C.T.S.).

References

- 1 Beal MF: Energetics in the pathogenesis of neurodegenerative diseases. *Trends Neurosci* 2000;23:298–304.
- 2 Reddy PH, Williams M, Tagle DA: Recent advances in understanding the pathogenesis of Huntington's disease. *Trends Neurosci* 1999;22:248–255.
- 3 Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF: Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. *Ann Neurol* 1997;41:646–653.
- 4 Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *J Neurosci* 1993;13:4181–4192.
- 5 Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M: 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. *Can J Neurol Sci* 1991;18:492–498.
- 6 Browne SE, Beal MF: The energetics of Huntington's disease. *Neurochem Res* 2004;29:531–546.
- 7 Kim GW, Chan PH: Involvement of superoxide in excitotoxicity and DNA fragmentation in striatal vulnerability in mice after treatment with the mitochondrial toxin, 3-nitropropionic acid. *J Cereb Blood Flow Metab* 2002;22:798–809.
- 8 Wei G, Hough CJ, Sarvey JM: The mitochondrial toxin, 3-nitropropionic acid, induces extracellular Zn²⁺ accumulation in rat hippocampus slices. *Neurosci Lett* 2004;370:118–122.

- 9 Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson's Disease: evidence supporting it. *Ann Neurol* 1992;32:804–812.
- 10 Jenner P, Olanow CW: Oxidative stress and the pathogenesis of Parkinson's disease. *Neurology* 1996;47:S161–S170.
- 11 Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB: Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. *J Neural Transm Suppl* 1995;46:297–314.
- 12 Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK: The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. *Neurochem Res* 1993;18:1175–1177.
- 13 Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, Oh YJ: Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. *J Neurosci Res* 1999;57:86–94.
- 14 Fonck C, Baudry M: Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation. *Brain Res* 2001;905:199–206.
- 15 Lee JY, Son HJ, Choi JH, Cho E, Kim J, Chung SJ, Hwang O, Koh JY: Cytosolic labile zinc accumulation in degenerating dopaminergic neurons of mouse brain after MPTP treatment. *Brain Res* 2009;1286:208–214.
- 16 Rojas P, Franco-Perez JE, Rojas C, Rojas-Castaneda J, Ebadi M, Fernandez-Valverde F, Serrano-Garcia N: Reduction of zinc-positive terminal fields in striatum of mouse after 1-methyl-4-phenylpyridinium neurotoxicity. *Neurotoxicology* 2005;26:959–968.
- 17 Sheline CT, Cai AL, Zhu J, Shi C: Serum or target deprivation-induced neuronal death causes oxidative neuronal accumulation of Zn²⁺ and loss of NAD⁺. *Eur J Neurosci* 2010;32:894–904.
- 18 Sheline CT, Choi DW: Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. *Neurobiol Dis* 1998;5:47–54.
- 19 Lotharius J, Dugan LL, O'Malley KL: Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. *J Neurosci* 1999;19:1284–1293.
- 20 Ying H, Gotttron F, Choi D: Assessment of cell viability in primary neuronal cultures. *Curr Protoc Neurosci* 2001;7:(chapt 7)18.
- 21 Cai AL, Zipfel GJ, Sheline CT: Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway. *Eur J Neurosci* 2006;24:2169–2176.
- 22 Sheline CT, Wei L: Free radical-mediated neurotoxicity may be caused by inhibition of mitochondrial dehydrogenases in vitro and in vivo. *Neuroscience* 2006;140:235–246.
- 23 Yang L, Calingasan NY, Chen J, Ley JJ, Becker DA, Beal MF: A novel azulenyl nitron antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. *Exp Neurol* 2005;191:86–93.
- 24 Cleren C, Calingasan NY, Chen J, Beal MF: Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. *J Neurochem* 2005;94:995–1004.
- 25 Martell AM, Smith RM, Motekaitis RJ: Critically Selected Stability Constants of Metal Complexes. NTIS Database. Version 3.0. Gaithersburg, US Dept of Commerce, 1997.
- 26 Beal MF: Neurochemistry and toxin models in Huntington's disease. *Curr Opin Neurol* 1994;7:542–547.
- 27 Sheline CT, Behrens MM, Choi DW: Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. *J Neurosci* 2000;20:3139–3146.
- 28 Stack EC, Matson WR, Ferrante RJ: Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. *Ann NY Acad Sci* 2008;1147:79–92.
- 29 Zhou C, Huang Y, Przedborski S: Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. *Ann NY Acad Sci* 2008;1147:93–104.
- 30 Browne SE: Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. *Ann N Y Acad Sci* 2008;1147:358–382.
- 31 Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF: Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. *Biochim Biophys Acta* 1802:122–134.
- 32 Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF: Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. *J Neurochem* 2009;109:1427–1439.
- 33 Rosenstock TR, Duarte AI, Rego AC: Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease – from clinical features to the bench. *Curr Drug Targets* 2010;11:1218–1236.
- 34 Zeviani M, Carelli V: Mitochondrial disorders. *Curr Opin Neurol* 2007;20:564–571.
- 35 Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J: Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. *J Biol Chem* 2004;279:18614–18622.
- 36 Schulz JB, Henshaw DR, Matthews RT, Beal MF: Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. *Exp Neurol* 1995;132:279–283.
- 37 Sugino T, Nozaki K, Tokime T, Hashimoto N, Kikuchi H: 3-nitropropionic acid induces poly(ADP-ribosylation) and apoptosis related gene expression in the striatum in vivo. *Neurosci Lett* 1997;237:121–124.
- 38 Cusi C, Marien M: Implication of poly(ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD⁺ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. *Ann N Y Acad Sci* 1999;890:227–239.
- 39 Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM: Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. *Proc Natl Acad Sci USA* 1999;96:5774–5779.
- 40 Bedalov A, Simon JA: Neuroscience. NAD to the rescue. *Science* 2004;305:954–955.
- 41 Hasbani DM, O'Malley KL: Wld(S) mice are protected against the parkinsonian mimetic MPTP. *Exp Neurol* 2006;202:93–99.
- 42 Press C, Milbrandt J: Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. *J Neurosci* 2008;28:4861–4871.
- 43 Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD: Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. *Proc Natl Acad Sci USA* 1999;96:1716–1721.
- 44 Erickson JC, Hollopeter G, Thomas SA, Froelich GJ, Palmiter RD: Disruption of the metallothionein-III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. *J Neurosci* 1997;17:1271–1281.
- 45 Mazzio EA, Reams RR, Soliman KF: The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. *Brain Res* 2004;1004:29–44.
- 46 Mazzio E, Soliman KF: The role of glycolysis and gluconeogenesis in the cytoprotection of neuroblastoma cells against 1-methyl 4-phenylpyridinium ion toxicity. *Neurotoxicology* 2003;24:137–147.
- 47 Mazzio E, Soliman KF: Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro. *Neurosci Lett* 2003;337:77–80.
- 48 Holleman MAF: Notice sur l'action de l'eau oxygénée sur les acides α -cétoniques et sur les dicétones 1.2. *Recl Trav Chim Pays Bas* 1904;23:169–171.
- 49 Sheline CT, Choi EH, Kim-Han JS, Dugan LL, Choi DW: Cofactors of mitochondrial enzymes attenuate copper-induced death in vitro and in vivo. *Ann Neurol* 2002;52:195–204.
- 50 Sheline CT, Choi DW: Cu²⁺ toxicity inhibition of mitochondrial dehydrogenases in vitro and in vivo. *Ann Neurol* 2004;55:645–653.
- 51 Sheline CT, Cai AL: Compounds which maintain the NAD⁺/NADH ratio attenuated neuronal death induced by MPP⁺, 6-hydroxydopamine, and 3-nitropropionic acid in vitro and in vivo. New Orleans, Society for Neuroscience, Online, 2003, abstract viewer/itinerary planner.